MedTrace Logo

Yellow Fever Immune Response at Single Cell Resolution

NCT03458780 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2026-07-14

No results posted yet for this study

Summary

The immune system is composed of diverse cell types with different functions that act together in order to defend against infection. This pilot study will test a new technology for studying these many different cell types at very large numbers at the level of individual cells. This method will then be used to identify the cell types and functions important for the immune response to the highly protective yellow fever vaccine, which will improve our understanding of effective vaccine features.

Conditions

  • Healthy

Interventions

DRUG

Yellow Fever Vaccine

Yellow Fever Vaccine .5 ml

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Brad R Rosenberg, MD, PhD · Icahn School of Medicine at Mount Sinai

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-22
Primary Completion
2018-09-05
Completion
2018-09-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03458780 on ClinicalTrials.gov